Skip to main content
Biology Letters logoLink to Biology Letters
. 2017 Nov 29;13(11):20170643. doi: 10.1098/rsbl.2017.0643

Associations between imprinted gene expression in the placenta, human fetal growth and preeclampsia

Julian K Christians 1,, Katherine Leavey 2, Brian J Cox 2,3
PMCID: PMC5719389  PMID: 29187609

Abstract

Genomic imprinting is essential for normal placental and fetal growth. One theory to explain the evolution of imprinting is the kinship theory (KT), which predicts that genes that are paternally expressed will promote fetal growth, whereas maternally expressed genes will suppress growth. We investigated the expression of imprinted genes using microarray measurements of expression in term placentae. Correlations between birthweight and the expression levels of imprinted genes were more significant than for non-imprinted genes, but did not tend to be positive for paternally expressed genes and negative for maternally expressed genes. Imprinted genes were more dysregulated in preeclampsia (a disorder associated with placental insufficiency) than randomly selected genes, and we observed an excess of patterns of dysregulation in preeclampsia that would be expected to reduce nutrient allocation to the fetus, given the predictions of the KT. However, we found no evidence of coordinated regulation among these imprinted genes. A few imprinted genes have previously been shown to be associated with fetal growth and preeclampsia, and our results indicate that this is true for a broader set of imprinted genes.

Keywords: placenta, imprinting, preeclampsia, intrauterine growth restriction, kinship theory

1. Introduction

Genomic imprinting is a phenomenon where the expression of an allele depends on whether it was inherited from the mother or the father. Many known imprinted genes in humans are expressed in the placenta and are essential for its normal function [1,2]. One theory to explain imprinting is the parental conflict theory, or kinship theory (KT), which proposes that there is a potential genetic conflict of interest between maternally and paternally inherited alleles [3,4]. Because of the possibility of multiple paternity, maternally inherited alleles are more likely to be related to alleles found in siblings who share a mother than are paternally inherited alleles. Therefore, paternally expressed genes (PEGs) are expected to promote the growth of the fetus, whereas maternally expressed genes (MEGs) are expected to constrain fetal growth to conserve resources so that they can be allocated more equally among a fetus and its siblings [1,5].

The expression levels of some imprinted genes have been correlated with fetal growth [6] and pregnancy complications associated with placental insufficiency such as preeclampsia (PE) and intrauterine growth restriction (IUGR) [5,7,8]. However, no study has systematically compared the expression of imprinted and non-imprinted genes in terms of associations with birthweight or pregnancy complications. Since the KT posits that imprinted genes are involved in nutrient allocation, this theory predicts that the placental expression of imprinted genes will be more strongly correlated with birthweight than non-imprinted genes. Imprinted genes are also expected to be dysregulated more than non-imprinted genes in PE and IUGR placentae, where nutrient delivery to the fetus is thought to be impaired. Furthermore, the KT predicts that increased expression of MEGs and decreased expression of PEGs will limit maternal investment in the fetus, whereas the opposite patterns will promote investment. The expression of imprinted genes might drive fetal growth and/or contribute to placental pathology, but imprinted genes might also take part in compensation for poor fetal growth and/or placental pathology, in which case the opposite expression patterns would be observed (figure 1). Furthermore, the expression of PEGs might counterbalance the expression of MEGs and vice versa, in which case no correlation between gene expression and birthweight or pathology would be observed (figure 1).

Figure 1.

Figure 1.

Patterns of gene expression for individual imprinted genes, and interpretations under the KT.

We used microarray measurements of gene expression in term placentae to test multiple predictions that follow from the KT. We tested (i) whether imprinted genes are more strongly correlated with birthweight than non-imprinted genes, (ii) whether imprinted genes are more dysregulated in PE and IUGR than non-imprinted genes, and (iii) whether there is an excess of patterns of expression expected to drive fetal growth/contribute to PE, or compensate for poor placental growth/placental insufficiency in PE (figure 1). We also hypothesized that genes showing the same patterns (i.e. expected to limit investment according to the KT or expected to promote investment) would be regulated by the same transcription factors. Therefore, we also tested (iv) whether there is evidence of coordinated regulation among genes showing limiting patterns according to the KT, and among genes showing promoting patterns, but not between these two sets, e.g. we would not expect a transcription factor in a pathway promoting maternal investment to downregulate some maternally expressed genes and upregulate others.

2. Material and methods

A list of 120 unique genes imprinted in humans was compiled [912] (electronic supplementary material, tables S1 and S2). We obtained expression data for 19 882 genes in 157 placental samples [13], all of which were used for analyses of birthweight. However, since PE and IUGR have diverse pathophysiology, we reduced heterogeneity by restricting our analyses to PE and IUGR samples from a single cluster (cluster 2) defined by clustering of gene expression; this cluster exhibits histopathological features of insufficient placental development [13]. Hence, the sample size was 117 for analyses of PE and IUGR (table 1). We removed genes annotated as ‘not detected’ in the placenta by Protein Atlas [14], leaving 14 986 genes, including 28 MEGs and 33 PEGs (electronic supplementary material, table S3). Clinical data included gestational age at delivery, occurrence of PE, occurrence of IUGR, birthweight (correcting for gestational age and sex) and offspring sex [13].

Table 1.

Gestational age at delivery (weeks).

PE + IUGR PE only IUGR only control
N 19 31 4 63
mean (s.d.) 30.8 (2.0) 31.9 (3.5) 32.6 (3.2) 34.9 (4.9)
range 27.0–34.1 26.9–39.3 29.4–37.1 25.9–41.1

For each gene, we performed a general linear model with gene expression as the dependent variable and terms for birthweight (or occurrence of IUGR), PE, fetal sex, and gestational age. This yielded, for each gene, F-statistics for the effects of birthweight (or IUGR) and preeclampsia on gene expression (electronic supplementary material, table S3). As measures of effect size, we obtained the slope of the regression of gene expression on birthweight or the fold change in gene expression between IUGR or PE and controls.

We tested whether the significance and effect size of imprinted genes were greater than would be expected for random genes. We selected genes at random from the complete set, such that the number of genes in the random sample was the same as the number of imprinted genes. We repeated this sampling 10 000 times to calculate null distributions for the F-statistic and effect size, with which we compared the values for imprinted genes.

To identify sets of imprinted genes showing an investment-limiting or -promoting pattern for PE or IUGR, we selected imprinted genes with significant effects (α = 0.05). PEGs with increased expression and MEGs with decreased expression in PE or IUGR were categorized as promoting investment whereas those showing the opposite pattern were categorized as limiting. To test for coordinated regulation among genes showing the same pattern, we calculated the proportion of variation explained by the first principal component within sets of genes and assessed whether this was greater within sets than between sets. To achieve this, we combined the limiting and promoting genes, divided them into two sets at random, and calculated the proportion of variation explained by the first principal component within each. The actual proportion of variation explained in each of the sets was compared with the null distribution from 10 000 randomizations. All analyses were performed in SAS, v. 9.4.

3. Results

The correlation between birthweight and the expression levels of imprinted genes was greater than that for randomly selected genes (p = 0.011; electronic supplementary material, figure S1). However, the directions of the correlations between imprinted genes and birthweight did not deviate from random, i.e. there was not an excess of the expected pattern (positive correlations between PEGs and birthweight, and negative correlations between MEGs and birthweight) or the reverse pattern (p = 0.21). If the expression of PEGs were counterbalancing the expression of MEGs or vice versa, we would expect an excess of positive correlations among PEGs and MEGs, but this was not observed (electronic supplementary material, table S4).

Imprinted genes were more dysregulated in PE than randomly selected genes (p = 0.032), but were not more dysregulated in IUGR than expected due to chance (p = 0.13; electronic supplementary material, figure S1). The direction of effects was consistent with imprinted genes limiting investment in pregnancies complicated by PE (i.e. PEGs downregulated and MEGs upregulated in PE; p = 0.021; table 2), with a similar but marginally non-significant pattern for IUGR (p = 0.082; table 2).

Table 2.

Statistical significance and effects of birthweight, preeclampsia, and intrauterine growth restriction (means ± s.e.; *imprinted genes significantly different from all genes at α = 0.05).

parameter all genes
(N = 14 986)
imprinted genes
(N = 61)
birthweight (continuous) F-statistic 3.88 ± 0.04 5.61 ± 0.88*
effect sizea 1.01 ± 0.00 1.00 ± 0.00
preeclampsia F-statistic 7.36 ± 0.10 10.56 ± 1.78*
effect sizea 1.00 ± 0.00 1.03 ± 0.02*
intrauterine growth restriction F-statistic 1.86 ± 0.02 2.24 ± 0.35
effect sizea 0.99 ± 0.00 1.01 ± 0.01

aFor all genes, a value less than 1 indicates a negative correlation between gene expression and birthweight, reduced expression in PE compared with controls, or reduced expression in IUGR compared with controls, whereas values greater than 1 indicate the opposite patterns. For imprinted genes, values less than 1 indicate patterns expected to promote investment in response to low birthweight/pathology, while values greater than 1 indicate patterns expected to drive fetal growth or contribute to PE/IUGR. More detailed description is provided in electronic supplementary material, table S3.

We tested for coordinated regulation among sets of genes showing limiting or promoting patterns, as predicted by the KT (electronic supplementary material, table S3). For PE, the correlation in expression levels was not greater within promoting genes (p = 0.28) or within limiting genes (p = 0.50) than between these two sets of genes. Similarly, there was no evidence of increased co-regulation in promoting or limiting genes (p = 0.84 and p = 0.22, respectively) categorized by dysregulation in IUGR.

4. Discussion

In general, imprinted genes had stronger correlations with birthweight and were more differentially expressed in PE than randomly selected genes. However, the directions of the correlations between birthweight and gene expression did not show an excess of patterns predicted to drive fetal growth according to the KT, and the pattern of up- and downregulation in IUGR was not significantly different from that of random genes.

In PE, the pattern of up- and downregulation was consistent with imprinted genes limiting maternal investment in complicated pregnancies (i.e. PEGs downregulated and MEGs upregulated in PE). A potential explanation for this result is that imprinted genes are contributing to placental pathology. Imprinted genes are often coordinately regulated [15], and if some imprinted genes were contributing to placental pathology, it would not be expected that each gene would be independently regulated; some genes would be regulated by the same transcription factors. However, we found no evidence of coordinated regulation among genes predicted to limit maternal investment based on the KT. This suggests that imprinted genes predicted by the KT to have similar effects in pathological pregnancies are not more likely to be part of a common pathway. Alternatively, some of these genes may not play roles in limiting or promoting maternal investment as predicted by the KT, potentially because the KT does not explain the imprinting of these genes.

Our study examined gene expression at the end of pregnancy, whereas nutrient allocation is determined much earlier. However, this limitation does not explain why imprinted genes showed stronger correlations with birthweight and greater dysregulation in PE than expected due to chance. While some imprinted genes have previously been shown to play important roles in placental development and function [1618], our results suggest that this is true for some other, less-studied imprinted genes. Further investigation into the expression patterns of imprinted genes will improve our understanding of the mechanisms underlying poor fetal growth and severe pregnancy complications.

Supplementary Material

Supplementary Tables 1-4
rsbl20170643supp1.xlsx (40.3KB, xlsx)

Supplementary Material

Supplementary Figure 1
rsbl20170643supp2.docx (295.8KB, docx)

Acknowledgements

We thank Bernard Crespi, Jon Wilkins and an anonymous referee for insightful comments on an earlier draft and Nicole Tortora for literature searches.

Ethics

This study required no ethical permit; all data were previously published.

Data accessibility

Data are available from the GEO database (accession no. GSE75010).

Authors' contributions

J.K.C. conceived of the study, carried out statistical analyses and drafted the manuscript. K.L. and B.J.C. contributed to analyses and interpretations, and helped draft the manuscript. All authors approve and are accountable for the final version.

Competing interests

We have no competing interests.

Funding

There was no funding for this study; all data were previously published.

References

  • 1.Frost JM, Moore GE. 2010. The importance of imprinting in the human placenta. PLoS Genet. 6, 1–9. ( 10.1371/journal.pgen.1001015) [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Renfree MB, Suzuki S, Kaneko-Ishino T. 2013. The origin and evolution of genomic imprinting and viviparity in mammals. Phil. Trans. R. Soc. B 368, 20120151 ( 10.1098/rstb.2012.0151) [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Haig D. 2014. Coadaptation and conflict, misconception and muddle, in the evolution of genomic imprinting. Heredity 113, 96–103. ( 10.1038/hdy.2013.97) [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Patten MM, Ross L, Curley JP, Queller DC, Bonduriansky R, Wolf JB. 2014. The evolution of genomic imprinting: theories, predictions and empirical tests. Heredity 113, 119–128. ( 10.1038/hdy.2014.29) [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Monk D. 2015. Genomic imprinting in the human placenta. Am. J. Obstet. Gynecol. 213, S152–S162. ( 10.1016/j.ajog.2015.06.032) [DOI] [PubMed] [Google Scholar]
  • 6.Moore GE, et al. 2015. The role and interaction of imprinted genes in human fetal growth. Phil. Trans. R. Soc. B 370, 20140074 ( 10.1098/rstb.2014.0074) [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.McMinn J, Wei M, Schupf N, Cusmai J, Johnson EB, Smith AC, Weksberg R, Thaker HM, Tycko B. 2006. Unbalanced placental expression of imprinted genes in human intrauterine growth restriction. Placenta 27, 540–549. ( 10.1016/j.placenta.2005.07.004) [DOI] [PubMed] [Google Scholar]
  • 8.Diplas AI, Lambertini L, Lee MJ, Sperling R, Lee YL, Wetmur J, Chen J. 2009. Differential expression of imprinted genes in normal and IUGR human placentas. Epigenetics 4, 235–240. ( 10.4161/epi.9019) [DOI] [PubMed] [Google Scholar]
  • 9.Morison IM, Ramsay JP, Spencer HG. 2005. A census of mammalian imprinting. Trends Genet. 21, 457–465. ( 10.1016/j.tig.2005.06.008) [DOI] [PubMed] [Google Scholar]
  • 10.Daelemans C, et al. 2010. High-throughput analysis of candidate imprinted genes and allele-specific gene expression in the human term placenta. BMC Genet. 11, 25 ( 10.1186/1471-2156-11-25) [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Barbaux S, et al. 2012. A genome-wide approach reveals novel imprinted genes expressed in the human placenta. Epigenetics 7, 1079–1090. ( 10.4161/epi.21495) [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Metsalu T, et al. 2014. Using RNA sequencing for identifying gene imprinting and random monoallelic expression in human placenta. Epigenetics 9, 1397–1409. ( 10.4161/15592294.2014.970052) [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Leavey K, Benton SJ, Grynspan D, Kingdom JC, Bainbridge SA, Cox BJ. 2016. Unsupervised placental gene expression profiling identifies clinically relevant subclasses of human preeclampsia. Hypertension 68, 137–147. ( 10.1161/HYPERTENSIONAHA.116.07293) [DOI] [PubMed] [Google Scholar]
  • 14.Uhlén M, et al. 2015. Tissue-based map of the human proteome. Science 347, 1260419 ( 10.1126/science.1260419) [DOI] [PubMed] [Google Scholar]
  • 15.Patten MM, Cowley M, Oakey RJ, Feil R. 2016. Regulatory links between imprinted genes: evolutionary predictions and consequences. Proc. R. Soc. B 283, 20152760 ( 10.1098/rspb.2015.2760) [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Coan PM, Burton GJ, Ferguson-Smith AC. 2005. Imprinted genes in the placenta—a review. Placenta 26(Suppl. A), S10–S20. ( 10.1016/j.placenta.2004.12.009) [DOI] [PubMed] [Google Scholar]
  • 17.Angiolini E, et al. 2006. Regulation of placental efficiency for nutrient transport by imprinted genes. Placenta 27, 98–102. ( 10.1016/j.placenta.2005.12.008) [DOI] [PubMed] [Google Scholar]
  • 18.Cleaton MAM, Edwards CA, Ferguson-Smith AC. 2014. Phenotypic outcomes of imprinted gene models in mice: elucidation of pre- and postnatal functions of imprinted genes. Annu. Rev. Genomics Hum. Genet. 15, 93–126. ( 10.1146/annurev-genom-091212-153441) [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Tables 1-4
rsbl20170643supp1.xlsx (40.3KB, xlsx)
Supplementary Figure 1
rsbl20170643supp2.docx (295.8KB, docx)

Data Availability Statement

Data are available from the GEO database (accession no. GSE75010).


Articles from Biology Letters are provided here courtesy of The Royal Society

RESOURCES